Humoral and cellular immune responses in atherosclerosis: Spotlight on B- and T-cells

Vascular Pharmacology

Volumn 56, Issue 5-6, 2012, Pages 193-203

  Ponnuswamy, Padmapriya ^a   Van Vré, Emily A ^a   Mallat, Ziad ^a,b   Tedgui, Alain ^a  

^a INSERM   (France)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atherosclerosis; B cells; Immunity; Inflammation; T cells

Indexed keywords

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; B LYMPHOCYTE; CELLULAR IMMUNITY; CULTURAL ANTHROPOLOGY; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; LIPID STORAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; DISEASE COURSE; IMMUNOLOGY;

ANIMALS; ATHEROSCLEROSIS; B-LYMPHOCYTES; DISEASE PROGRESSION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; T-LYMPHOCYTES;

EID: 84861317678     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.01.009     Document Type: Review

References (157)

1. Agrawal S., et al. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation 2007, 115:2939-2947.
2. Ait-Oufella H., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 2006, 12:178-180.
3. Ait-Oufella H., et al. B cell depletion reduces the development of atherosclerosis in mice. J. Exp. Med. 2010, 207:1579-1587.
4. Aslanian A.M., et al. Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2005, 25:628-632.
5. Aubry M.C., et al. B-lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. Cardiovasc. Pathol. 2004, 13:233-236.
6. Banchereau J., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
7. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat. Rev. Immunol. 2011, 11:34-46.
8. Bellinghausen I., et al. Production of interleukin-13 by human dendritic cells after stimulation with protein allergens is a key factor for induction of T helper 2 cytokines and is associated with activation of signal transducer and activator of transcription-6. Immunology 2003, 108:167-176.
9. Bendelac A., et al. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995, 268:863-865.
10. Binder C.J., et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 2004, 114:427-437.
11. Borish L.C., Steinke J.W. Cytokines and chemokines. J. Allergy Clin. Immunol. 2003, 111:S460-S475. 2.
12. Buono C., et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1596-1601.
13. Caligiuri G., et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 2002, 109:745-753.
14. Chen S., et al. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J. Immunol. 2010, 185:5619-5627.
15. Cheng X., et al. Inhibition of IL-17A in atherosclerosis. Atherosclerosis 2011, 215:471-474.
16. Choi J.H., et al. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity 2011, 35:819-831.
17. Daissormont I.T., et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ. Res. 2011, 109:1387-1395.
18. Danzaki K., et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:273-280.
19. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 2003, 163:1117-1125.
20. de Boer O.J., et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2:e779.
21. DiLillo D.J., et al. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. N. Y. Acad. Sci. 2010, 1183:38-57.
22. DiLillo D.J., et al. B-lymphocyte effector functions in health and disease. Immunol. Res. 2011, 49:281-292.
23. Ding Q., et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 2011, 121:3645-3656.
24. Doran A.C., et al. B-cell aortic homing and atheroprotection depend on Id3. Circ. Res. 2012, 110:e1-e12.
25. Dotevall A., et al. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin. Sci. (Lond.) 2001, 101:523-531.
26. Eid R.E., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
27. Elhage R., et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 2003, 59:234-240.
28. Elhage R., et al. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am. J. Pathol. 2004, 165:2013-2018.
29. Elsheikh E., et al. Anti-endothelial cell antibodies are increased in patients with previous myocardial infarction. Scand. Cardiovasc. J. 2010, 44:255-259.
30. Erbel C., et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J. Immunol. 2009, 183:8167-8175.
31. Erbel C., et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res. Cardiol. 2011, 106:125-134.
32. Faria-Neto J.R., et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006, 189:83-90.
33. -/- mice. Cardiovasc. Res. 2009, 84:155-163.
34. Ferber I.A., et al. GATA-3 significantly downregulates IFN-gamma production from developing Th1 cells in addition to inducing IL-4 and IL-5 levels. Clin. Immunol. 1999, 91:134-144.
35. Foks A.C., et al. Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis 2011, 218:53-60.
36. Foteinos G., et al. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 2005, 112:1206-1213.
37. Frostegard J., et al. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler. Thromb. 1992, 12:461-467.
38. Frostegard J., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33-43.
39. Galkina E., et al. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J. Exp. Med. 2006, 203:1273-1282.
40. Gao Q., et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J. Immunol. 2010, 185:5820-5827.
41. Godfrey D.I., et al. Raising the NKT cell family. Nat. Immunol. 2010, 11:197-206.
42. Gotsman I., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114:2047-2055.
43. -/- mice. J. Exp. Med. 2009, 206:233-248.
44. Gupta S., et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 1997, 99:2752-2761.
45. Han S.F., et al. The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin. Immunol. 2007, 124:90-97.
46. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 2011, 12:204-212.
47. Hermansson A., et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J. Exp. Med. 2010, 207:1081-1093.
48. Hernandez-Vargas P., et al. Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ. Res. 2006, 99:1188-1196.
49. Huang Y., et al. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1600-1607.
50. Huber S.A., et al. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 2001, 103:2610-2616.
51. Hulthe J., et al. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler. Thromb. Vasc. Biol. 2001, 21:101-107.
52. Ji Q.W., et al. Downregulation of T helper cell type 3 in patients with acute coronary syndrome. Arch. Med. Res. 2009, 40:285-293.
53. Ju X., et al. Review of human DC subtypes. Meth. Mol. Biol. 2010, 595:3-20.
54. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 2003, 3:984-993.
55. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22:456-461.
56. King V.L., et al. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am. J. Pathol. 2007, 171:2040-2047.
57. Kocsis J., et al. Antibodies against the human heat shock protein hsp70 in patients with severe coronary artery disease. Immunol. Investig. 2002, 31:219-231.
58. Kural B.V., et al. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron. Artery Dis. 2004, 15:277-283.
59. Kurata H., et al. Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity 1999, 11:677-688.
60. Kyaw T., et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J. Immunol. 2010, 185:4410-4419.
61. Kyaw T., et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ. Res. 2011, 109:830-840.
62. Kyriakakis E., et al. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur. J. Immunol. 2010, 40:3268-3279.
63. Kyriakakis E., et al. IL-8-mediated angiogenic responses of endothelial cells to lipid antigen activation of iNKT cells depend on EGFR transactivation. J. Leukoc. Biol. 2011, 90:929-939.
64. Lahoute C., et al. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat. Rev. Cardiol. 2011, 8:348-358.
65. Lai Y.H., Mosmann T.R. Mouse IL-13 enhances antibody production in vivo and acts directly on B cells in vitro to increase survival and hence antibody production. J. Immunol. 1999, 162:78-87.
66. Lazarevic V., et al. T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORgammat. Nat. Immunol. 2011, 12:96-104.
67. Lee T.S., et al. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:734-742.
68. Lewis M.J., et al. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009, 120:417-426.
69. Lim W.S., et al. Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation 2008, 117:940-951.
70. Lin J., et al. The role of CD4+CD25+ regulatory T cells in macrophage-derived foam-cell formation. J. Lipid Res. 2010, 51:1208-1217.
71. Liossis S.N., Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin. Immunol. 2008, 127:280-285.
72. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
73. Lutgens E., et al. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 1999, 5:1313-1316.
74. Lutgens E., et al. CD40 and its ligand in atherosclerosis. Trends Cardiovasc. Med. 2007, 17:118-123.
75. Lutgens E., et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 2010, 207:391-404.
76. Mach F., et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200-203.
77. Maganto-Garcia E., et al. Foxp3+-inducible regulatory T cells suppress endothelial activation and leukocyte recruitment. J. Immunol. 2011, 187:3521-3529.
78. Maganto-Garcia E., et al. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation 2011, 124:185-195.
79. Major A.S., et al. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1892-1898.
80. Major A.S., et al. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2351-2357.
81. Mallat Z., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 2001, 89:E41-E45.
82. Mallat Z., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 2001, 89:930-934.
83. Mallat Z., et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003, 108:1232-1237.
84. Mallat Z., et al. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc. Med. 2007, 17:113-118.
85. Mantovani A., et al. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1419-1423.
86. Martin F., Kearney J.F. B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 2001, 13:195-201.
87. Matsushita T., et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 2008, 118:3420-3430.
88. Mendez-Fernandez Y.V., et al. The inhibitory FcgammaRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice. Atherosclerosis 2011, 214:73-80.
89. Miller A.M., et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 2008, 205:339-346.
90. Miller Y.I., et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 2011, 108:235-248.
91. Montes R., et al. Autoantibodies against the endothelial receptor of protein C are associated with acute myocardial infarction in young women. J. Thromb. Haemost. 2005, 3:1454-1458.
92. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
93. Mor A., et al. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur. Heart J. 2006, 27:2530-2537.
94. Mor A., et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:893-900.
95. Moreira A.P., et al. The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A. J. Clin. Invest. 2011, 121:4420-4432.
96. Munro J.M., et al. An immunohistochemical analysis of human aortic fatty streaks. Hum. Pathol. 1987, 18:375-380.
97. Munzel T., et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann. Med. 2008, 40:180-196.
98. Nakai Y., et al. Natural killer T cells accelerate atherogenesis in mice. Blood 2004, 104:2051-2059.
99. Ng H.P., et al. Attenuated atherosclerotic lesions in apoE-Fcgamma-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J. Immunol. 2011, 187:6082-6093.
100. Ohshima Y., et al. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998, 92:3338-3345.
101. Orem C., et al. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron. Artery Dis. 2002, 13:65-71.
102. Ostos M.A., et al. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett. 2002, 519:23-29.
103. Ouyang W., et al. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
104. Paigen B., et al. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985, 57:65-73.
105. Paulson K.E., et al. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ. Res. 2010, 106:383-390.
106. Pereira I.A., Borba E.F. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med. Wkly 2008, 138:534-539.
107. Pham T., et al. Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. Blood 2009, 114:5225-5235.
108. Potteaux S., et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1474-1478.
109. Pratico D., et al. Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation by vitamin E. Blood 2001, 97:459-464.
110. Rincon M., et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J. Exp. Med. 1997, 185:461-469.
111. Robertson A.K., et al. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 2003, 112:1342-1350.
112. Roger V.L., et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
113. Rogers L., et al. Deficiency of invariant V alpha 14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. Cardiovasc. Res. 2008, 78:167-174.
114. Sasaki N., et al. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 2009, 120:1996-2005.
115. Shaposhnik Z., et al. Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2007, 27:621-627.
116. Shoenfeld Y., et al. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 2004, 110:2552-2558.
117. Sjogren P., et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur. Heart J. 2008, 29:2218-2226.
118. Smith E., et al. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through "short-loop" inhibition via IL-17 receptor. J. Immunol. 2008, 181:1357-1364.
119. Smith E., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
120. Stemme S., et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3893-3897.
121. Strom A., et al. Involvement of the CD1d-natural killer T cell pathway in neointima formation after vascular injury. Circ. Res. 2007, 101:e83-e89.
122. Szabo S.J., et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
123. Taleb S., et al. Regulatory T-cell immunity and its relevance to atherosclerosis. J. Intern. Med. 2008, 263:489-499.
124. Taleb S., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 2009, 206:2067-2077.
125. Taleb S., et al. Interleukin-17: friend or foe in atherosclerosis?. Curr. Opin. Lipidol. 2010, 21:404-408.
126. Tan J.Q., et al. Type I natural killer T cells: naturally born for fighting. Acta Pharmacol. Sin. 2010, 31:1123-1132.
127. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 2006, 86:515-581.
128. Tsimikas S., et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J. Lipid Res. 2007, 48:425-433.
129. Tupin E., et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 2004, 199:417-422.
130. van Es T., et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem. Biophys. Res. Commun. 2009, 388:261-265.
131. van Es T., et al. Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. Atherosclerosis 2010, 209:74-80.
132. Van Kaer L., et al. Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res. 2011, 343:43-55.
133. van Leeuwen M., et al. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun. Rev. 2009, 9:53-57.
134. van Puijvelde G.H., et al. Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb. Haemost. 2009, 102:223-230.
135. Van Vre E.A., et al. Immunohistochemical characterisation of dendritic cells in human atherosclerotic lesions: possible pitfalls. Pathology 2011, 43:239-247.
136. Van Vre E.A., et al. Dendritic cells in human atherosclerosis: from circulation to atherosclerotic plaques. Mediat. Inflamm. 2011, 2011:941396.
137. van Wanrooij E.J., et al. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:204-210.
138. VanderLaan P.A., et al. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am. J. Pathol. 2007, 170:1100-1107.
139. Vink A., et al. Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population. J. Exp. Med. 1999, 189:1413-1423.
140. Vitale G., et al. Regulatory B cells: evidence, developmental origin and population diversity. Mol. Immunol. 2010, 48:1-8.
141. -/- mice. J. Clin. Invest. 2011, 121:3564-3577.
142. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
143. Weber C., et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J. Clin. Invest. 2011, 121:2898-2910.
144. -/- mice. Am. J. Pathol. 2000, 157:1819-1824.
145. Whitman S.C., et al. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ. Res. 2002, 90:E34-E38.
146. Wigren M., et al. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ. Res. 2009, 104:e62-e70.
147. Wolf S.D., et al. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 1996, 184:2271-2278.
148. Wu R., et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 1997, 17:3159-3163.
149. Xie J.J., et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010, 49:185-193.
150. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1547-1559.
151. Xu Q., et al. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J. Clin. Invest. 1993, 91:2693-2702.
152. Xu Q., et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993, 341:255-259.
153. Xu Q., et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999, 100:1169-1174.
154. Yanaba K., et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
155. Zhang X., et al. Plasma levels of Hsp70 and anti-Hsp70 antibody predict risk of acute coronary syndrome. Cell Stress Chaperones 2010, 15:675-686.
156. Zhou X., Hansson G.K. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand. J. Immunol. 1999, 50:25-30.
157. Zhou X., et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102:2919-2922.